NCT03951181

Brief Summary

The investigators know that many people with multiple sclerosis (MS) require support to remain physically active and often do not receive any or enough support. This is particularly the case for People with Progressive MS (PwPMS) with moderate to severe disability - those who require assistance to mobilise (i.e. using a stick, frame or wheelchair) and/or have other MS related symptoms such as fatigue and difficulties remembering. In Phase 1 of the LEAP-MS study the investigators collected information about the barriers to and facilitators of physical activity (PA) that PwPMS experience, their current levels and type of physical activity and their perceptions of the role physical activity plays in managing MS symptoms from both them and their families - or people that support them. This provided important information about why physical activity might be important for PwPMS, the challenges they face in doing physical activity or accessing it, and ways which they have found to overcome any barriers. The investigators also collected information from physiotherapists and other health care professionals who specialise in treating people with MS, about their understanding of self-management and their needs for training about using self-management approaches with PwPMS. The investigators used this information to co-produce (with the involvement of PwPMS patients and physiotherapists/healthcare professionals) a personalised intervention; Life-style, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS) to facilitate on-going physical activity for people with PwPMS and a training package about self-management with PwPMS for physiotherapists. In this feasibility study the investigators will evaluate the acceptability of the LEAP-MS intervention. The investigators will also evaluate feasibility of conducting a future trial of the intervention in terms of recruitment, retention, adherence (usage), outcome measures and safety evaluation and establishing fidelity of intervention delivery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable multiple-sclerosis

Timeline
Completed

Started Aug 2020

Shorter than P25 for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 15, 2019

Completed
1.2 years until next milestone

Study Start

First participant enrolled

August 13, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 19, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 19, 2021

Completed
Last Updated

July 2, 2021

Status Verified

March 1, 2021

Enrollment Period

8 months

First QC Date

May 7, 2019

Last Update Submit

July 1, 2021

Conditions

Outcome Measures

Primary Outcomes (7)

  • Recruitment rate

    assessed as the percentage of those submitting online permission to contact forms who are eligible and who consent to participation. The primary outcome will be based on the feasibility of the study in terms of quantitative measures of recruitment, retention and intervention uptake. These proportions will be tabulated with 95% confidence intervals alongside the CONSORT chart. No formal hypothesis tests will be carried out in the analysis. Intervention uptake data will be summarised based on the proportion of participants engaging with the intervention. Factors such as disease severity (as represented by EDSS scores) and self-efficacy that may plausibly impact on intervention uptake and retention will be explored. Safety data will be collected through self-reporting by the participant on the digital interactive education and activity tool. Acceptability of the intervention to both PwPMS and physiotherapists (usability, content, design, and language) and fidelity will be assessed.

    6 months

  • Retention rate

    will be measured as the percentage of individuals who complete the 3 and 6 month follow-up assessments

    6 months

  • Intervention uptake

    will be defined as percentage of intervention sessions completed which may be reflected as number of completed physiotherapy led coaching sessions and number of remote physiotherapist contacts, website log in rates, length of time between each log in episode and duration of logged activity.

    6 months

  • Costs associated with intervention delivery

    potential therapist travel and contact time will be recorded

    6 months

  • Incidence of Treatment-Emergent Adverse Events

    will be assessed by an online process of self-reporting by the participant

    6 months

  • Acceptability assessment (process evaluation)

    will focus on content, design, language and adaptability to personal needs and will be assessed through use of any remote contact facility and semi-structured interviews (either face to face or by telephone) with participants who completed the intervention and physiotherapists who delivered the intervention

    6 months

  • Fidelity of intervention delivery

    will be assessed through sampled observations of interactive physiotherapy consultations.

    6 months

Study Arms (1)

LEAP-MS Intervention

EXPERIMENTAL

This is a single arm study.

Behavioral: LEAP-MS

Interventions

LEAP-MSBEHAVIORAL

The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.

LEAP-MS Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • People aged 18 and over
  • With progressive MS
  • Having an Expanded Disability Status Scale (EDSS) score of 6, 6.5, 7, 7.5 or 8.

You may not qualify if:

  • aged under 18
  • an EDSS \<6 or \>8
  • relapsing-remitting or non-progressive MS
  • unable to understand written and spoken English
  • lacking capacity to consent on their own behalf
  • pregnant or planning a pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre for Trials Research

Cardiff, CF144YS, United Kingdom

Location

Related Publications (2)

  • Latchem-Hastings J, Randell E, Button K, Jones F, Lowe R, Dawes H, Wood F, Davies F, Poile V, O'Halloran R, Stensland B, Tallantyre E, Playle R, Edwards A, Busse M. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot Feasibility Stud. 2021 May 22;7(1):111. doi: 10.1186/s40814-021-00852-w.

  • Lowe R, Barlow C, Lloyd B, Latchem-Hastings J, Poile V, Scoble C, Dean-Young A, Button K, Playle R, Busse M. Lifestyle, Exercise and Activity Package for People living with Progressive Multiple Sclerosis (LEAP-MS): adaptions during the COVID-19 pandemic and remote delivery for improved efficiency. Trials. 2021 Apr 16;22(1):286. doi: 10.1186/s13063-021-05245-1.

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Monica Busse

    Cardiff Unviersity

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2019

First Posted

May 15, 2019

Study Start

August 13, 2020

Primary Completion

April 19, 2021

Study Completion

April 19, 2021

Last Updated

July 2, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations